We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder.
- Authors
Nierenberg, Andrew A.; Trivedi, Madhukar H.; Gaynes, Bradley N.; Mitchell, Jeff; Davis, Lori L.; Husain, Mustafa M.; Wisniewski, Stephen R.; Fava, Maurizio; Warden, Diane; Luther, James F.; van Nieuwenhuizen, Adrienne O.; Morris, David W.; Shelton, Richard C.; John Rush, A.
- Abstract
Objective: Although the second-generation antipsychotic, aripiprazole (ARI), has been approved as an adjunct for treatment-resistant major depressive disorder (MDD), neither ARI nor any second-generation antipsychotic has been assessed in combination with an antidepressant at the initiation of a treatment trial for non-treatment-resistant MDD. The aim of the present study was therefore to assess the safety, tolerability, and remission rate in the treatment of MDD using the specific combination of venlafaxine-XR (VEN-XR) and ARI in a generalizable, difficult-to-treat group with chronic or recurrent MDD. Methods: Self-declared participants in primary care or psychiatric settings who had chronic or recurrent MDD and a minimum score of 14 on the 17-item Hamilton Rating Scale for Depression were included. Up to 12 weeks of open treatment with the combination of VEN-XR and ARI was provided. Participants began with VEN-XR, and ARI was added at week 2. Maximum allowable doses were 300 mg day-1 for venlafaxine-XR and 30 mg day-1 for ARI. Remission was defined as ≤ 5 on the 16-item Quick Inventory of Depressive Symptomatology-Self-report (QIDS-SR16). Results: Fifty outpatients with non-psychotic MDD were enrolled (mean age = 43±11 years; 38% male; QIDS-SR16=15±3). Mean exit dose of VEN-XR was 227±97 mg day-1, and the mean exit dose of ARI was 11±7 mg day-1. The combination was well tolerated; 16% of participants discontinued due to side-effects. Approximately 70% achieved remission at some point during the trial, and 66% achieved remission at study exit. Conclusions: To the best of the authors' knowledge this is the first study to combine an antidepressant and second-generation antipsychotic at the beginning of a treatment trial for chronic or recurrent non-treatment resistant MDD. VEN-XR and ARI combination appears to warrant further study in controlled trials.
- Subjects
VENLAFAXINE; ANTIDEPRESSANTS; MENTAL depression; PATHOLOGICAL psychology; PRIMARY care
- Publication
Australian & New Zealand Journal of Psychiatry, 2009, Vol 43, Issue 10, p956
- ISSN
0004-8674
- Publication type
Article
- DOI
10.1080/00048670903001885